Lyra Therapeutics

Biotechnology ResearchMassachusetts, United States11-50 Employees

Lyra Therapeutics is a clinical-stage biotechnology company based in Watertown, Massachusetts, operating in the biotechnology research sector. It pursues therapies for the localized treatment of chronic rhinosinusitis, an inflammatory disease of the paranasal sinuses with debilitating symptoms. The company leverages a focus on delivering medicines directly to the affected tissue, aiming for sustained exposure from a single administration.

Its product candidates, LYR-210 and LYR-220, are bioresorbable polymer matrices intended for brief in-office administration and designed to provide up to six months of continuous mometasone furoate to the sinonasal passages. This approach targets CRS symptoms in a focused manner, reducing the need for repeated dosing over time. Built on expertise in materials science and drug formulation, the company emphasizes controlled, localized delivery as its core development pathway.

Sign up for free to view info

Email Format Employee directory